全部商品分类
ANTI-MO GRANZYME B 16G6 BIOTIN
下载产品说明书 下载COA 下载SDS
用小程序，查商品更便捷
收藏
对比
咨询
种属反应
已发表种属
宿主/亚型
分类
类型
克隆号
偶联物
形式
浓度
纯化类型
保存液
内含物
保存条件
运输条件
RRID
产品详细信息
Description: The 16G6 antibody reacts with mouse Granzyme B (GrB) which is a member of the granzyme serine protease family. GrB is found in the granules of cytotoxic T cells and NK cells. Granzyme B has also been described as CGL1 (cathepsin G-like-1), a serine protease expressed only in cytotoxic T-lymphocytes after cell activation. GrB has been called CTLA-1 (cytotoxic T lymphocyte-associated serine esterase 1) based on identification of mRNA in various cytotoxic T cells, but not observed in non-cytotoxic lymphoid cells. GrB is crucial for the rapid induction of target cell death by apoptosis, induced by interaction with cytotoxic T cells. The receptor involved has been identified as mannose 6-phosphate receptor. This receptor functions as a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.
For intracellular staining and flow cytometric analysis with direct conjugates of anti-mouse Granzyme B, it is highly recommended to use the Foxp3 Staining Buffer Set (Product # 00-5523). Other buffers may yield varying results.
Applications Reported: This 16G6 antibody has been reported for use in intracellular staining followed by flow cytometric analysis, western blotting, and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections.
Applications Tested: The biotinylated 16G6 antibody has been tested by immunoblotting (WB); a recommended starting concentration is 1 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Filtration: 0.2 µm post-manufacturing filtered.
靶标信息
Granzyme B is a member of the granzyme serine protease family, and is found in the granules of cytotoxic T cells and NK cells. Granzyme B has been described as CGL1 (cathepsin G-like-1), a serine protease expressed only in cytotoxic T-lymphocytes after cell activation, and CTLA-1 (cytotoxic T lymphocyte-associated serine esterase 1) based on identification of mRNA in various cytotoxic T cells, but not observed in non-cytotoxic lymphoid cells. Granzyme B is crucial for the rapid induction of target cell death by apoptosis, induced by interaction with cytotoxic T cells. The receptor involved in this process has been identified as mannose 6-phosphate receptor which functions as a death receptor for Granzyme B during cytotoxic T cell-induced apoptosis. Granzyme B enters target cells to cleave caspase-3 and initiate the caspase cascade leading to DNA fragmentation and apoptosis. Granzyme B can also act through a mitochondrial apoptosis pathway by cleaving the Bid protein. Granzymes are neutral serine proteases, which are stored in specialized lytic granules of cytotoxic T lymphocytes (CTLs) and in natural killer (NK) cells. A number of granzymes (A to G) have been isolated and cloned from mouse CTLs and NK cells, however in man, fewer have been cloned and identified.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
生物信息学
蛋白别名: CCP1; CTLA-1; Cytotoxic cell protease 1; Cytotoxic T lymphocyte associated serine esterase 1; Fragmentin-2; Granzyme B(G,H); GranzymeB; Human lymphocyte protein (Hlp); OTTHUMP00000028189
基因别名: AI553453; CCP-1/C11; CCP1; Ctla-1; Ctla1; GZB; Gzmb
UniProt ID:(Mouse) P04187
Entrez Gene ID:(Mouse) 14939
参考图片
BALB/c splenocytes were stimulated with Mouse IL-2 Recombinant protein (100 ng/mL) (Product # 14-8021-64) for 3 days. Subsequently, splenocyte lysates were loaded at 1x10e6 cells/lane, probed with 1 µg/mL Anti-Mouse Granzyme B Purified and revealed with HRP anti-rat IgG.
Published figure using Granzyme B monoclonal antibody (Product # 13-8822-82) in Western Blot
Published figure using Granzyme B monoclonal antibody (Product # 13-8822-82) in Western Blot
Published figure using Granzyme B monoclonal antibody (Product # 13-8822-82) in Western Blot
Figure 4 SFIH combined with an anti-PD-1 antibody alters the immune landscape in the tumor microenvironment. Immunohistochemistry (IHC) staining of MC38 tumors for infiltration of immune cells. CD3, CD8, granzyme B, F4/80, and TGF-beta1 levels were assessed by microscopic examination of IHC-stained sections. Representative IHC-stained images are shown (scale bars = 100 um).
Figure 3 CD73 presents a negative spatial correlation with anti-tumor immunity. (A, C) Analysis of Granzyme B IHC staining from RFA + AB680 treated tumors 10 days after ablation revealed increased abundance of Granzyme B + cells when compared to KPC control tumors subcutaneously grown up to 10 days (p < 0.0001), RFA (p < 0.01) and RFA+VEH (p < 0.01) treated mice . (B, D) Analysis of CD8alpha positive cells IHC staining from RFA + AB680 treated tumors 10 days after ablation revealed increased abundance of CD8alpha + cells when compared to KPC control tumors subcutaneously grown up to 10 days, RFA and RFA+VEH treated mice (p < 0.0001). (E) At 10 days after treatment, a negative correlation was observed between CD73 protein expression (Left) and abundance of Granzyme B + cells (Right) in composite pictures of RFA treated KPC subcutaneous tumors taken at 4X after IHC. (F) Higher magnification images reveal areas with decreased CD73 expression present increased granzyme B+ cells (Left panels, a and b), whereas areas with increased CD73 expression show decreased Granzyme B+ cells (Right panels, c and d), suggesting elevated antitumor immunity in areas with lower ADO generation. One-way ANOVA (C, D) were used for group comparisons. Bars represent 50uM. **p<0.01; ****p<0.0001; ns (not significant).
Published figure using Granzyme B monoclonal antibody (Product # 13-8822-82) in Immunohistochemistry